Klaire Labs (SFI USA) Announces Target gb-X™
The first commercially available gut-brain focused probiotic blend for clinically-demonstrated mood support
Klaire Labs (SFI USA) announced availability of Target gb-X™ with Ecologic BARRIER, a unique nine-strain blend to support positive mood. This shelf stable, 5B CFU probiotic was specifically designed to influence the gut-brain axis through defined mechanisms including strengthening of the gut barrier function, modulation of cytokines and inflammatory response, neuroprotective metabolite production, and HPA axis.
Target gb-X™ was formulated and developed in partnership with Winclove Probiotics (Amsterdam, NL), a company that researches, develops and manufactures evidence-based probiotics.
"Target gb-X™ is a clinically-researched, safe, and effective way to support patients with mood-related concerns," said Jeremy Appleton, ND, Vice President of Regulatory Affairs at Klaire Labs. "This product is the first in a line of Klaire Labs' targeted, indication-specific probiotics. We are very excited to continually support our practitioner partners with innovative, evidence-based products."
The product will be launched officially at the Integrative Healthcare Symposium (IHS) in New York, 22-24 Feb. Klaire Labs will be sponsoring an evening symposium discussing the mechanisms, the clinical evidence, and one psychiatrist's experience with the formulation.
Target gb-X™ is currently available for pre-order. This formulation is available as shelf-stable, hypoallergenic*, non-GMO, single serving sachets. For more information and product updates, visit meetklaire.com or stop by the Klaire Labs booth (100) at IHS.
*Free of the following common allergens: milk/casein, fish, shellfish, tree nuts, peanuts, wheat, gluten, and soybeans. No artificial additives, colors, flavorings, preservatives, sugar, or salicylates are used. Contains corn.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease
About Klaire Labs
Klaire Labs has been formulating and manufacturing premium, hypoallergenic supplements sold through healthcare practitioners for nearly half a century. Our mission is to develop and manufacture the purest, most potent nutraceuticals possible, thereby empowering clinicians with consistently reliable performance.
Klaire Labs is located in Reno, Nevada. It is owned by Soho Flordis International, a privately held nutraceutical company based in Sydney, Australia.
BrandHive for Klaire Labs